Comparative Pharmacology
Head-to-head clinical analysis: CIPRO versus FLOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO versus FLOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
CIPRO vs FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription, leading to bacterial cell death.
Of course, I can help you with that. However, I must clarify that there is no drug called "FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER". "Floxin" is a brand name for ofloxacin, an antibiotic. Ofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Ciprofloxacin 500 mg PO q12h or 400 mg IV q12h for uncomplicated infections; 750 mg PO q12h or 400 mg IV q8h for severe/complicated infections.
400 mg (as ofloxacin) intravenously every 12 hours for 7-14 days.
None Documented
None Documented
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCiprofloxacin + Deslanoside
"Ciprofloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCiprofloxacin + Acetyldigitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 3-5 hours (normal renal function), extended to 8-10 hours in mild-to-moderate renal impairment (CrCl 30-50 mL/min) and up to >10 hours in severe impairment (CrCl <30 mL/min); half-life in elderly may be 5-8 hours due to reduced clearance.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases).
Renal (50-70% unchanged via glomerular filtration and tubular secretion); biliary/fecal (15-20%, primarily as metabolites); small amount metabolized to 4 metabolites (oxo-, sulfo-, and desethylene-ciprofloxacin).
Primarily renal (80-90% unchanged); biliary/fecal <4%.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic